Grupo de investigación cardiovascular
GRINCAR
University of Minnesota
Mineápolis, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Minnesota (7)
2022
-
Assessment of Omecamtiv Mecarbil for the Treatment of Patients with Severe Heart Failure: A Post Hoc Analysis of Data from the GALACTIC-HF Randomized Clinical Trial
JAMA Cardiology, Vol. 7, Núm. 1, pp. 26-34
2021
-
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116
2020
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171
2016
-
Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II
European Heart Journal, Vol. 37, Núm. 33, pp. 2591-2601
2012
-
Concordance among pathologists in the second cardiac allograft rejection gene expression observational study (CARGO II)
Transplantation, Vol. 94, Núm. 11, pp. 1172-1177
2008
-
Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation
Clinical Transplantation, Vol. 22, Núm. 6, pp. 809-814
2007
-
Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients
Clinical Transplantation, Vol. 21, Núm. 1, pp. 18-23